Obesity is a chronic, relapsing, multifactorial, neurological disease, wherein an increase in body fat results in adverse metabolic, bio-mechanical, and psychosocial health consequences. Despite its major impact on health and quality of life, there are limited treatment options apart from bariatric surgery.
XEN-101 is an investigational treatment for obesity planned to be evaluated in a Phase I clinical trial. XEN-101 is a first-in-class oral formulation, engineered to produce weight loss by mimicking the microbiome changes induced by gastric bypass surgery. XEN-101 demonstrated profound weight loss effects in animal models and humans with limited side effects.
Xeno Biosciences is a clinical-stage company led by an experienced team, dedicated to developing transformational therapies for metabolic diseases.
